Press Release November 2004
The following is supportive data to the attached abstract and patient performance data
on this breaking story.
The Prostatitis & Prostate Cancer Center
With a new case of prostate cancer diagnosed every 3 minutes, there is concern that without novel, beneficial,
less costly methodologies to treat the cancer the health care system will be at risk. The late William Fair,
M.D. (former Chairman of Surgery and Urology at Memorial Sloan-Kettering), who championed the cause of
Integrative Medicine, stated in the year 2000, "Based on everything we know about prostate cancer, I am not
certain that it should not be treated as a chronic disease." Dr. Fair's frustration was noted in the inability
to predictably cure prostate cancer when it was detected. Challenging the concept of treatment for cure, the
late Willet Whitmore, M.D. (Memorial Sloan-Kettering) asked the rhetorical question in a now famous quote, "Is
it possible to cure prostate cancer when it is necessary and is it necessary to cure prostate cancer when it is
Concentrating on the later part of the rhetorical question, I have evaluated men with known prostate cancer with
a modified Mediterranean diet and a patented prostate nutritional formula called Peenuts®. I believe I have
developed a viable treatment modality for men with moderately well differentiated prostate cancer. The results
of this prospective study are exceptional as the prostate cancer process has just reversed itself or stopped
growing. Importantly, all men entered in the study did well. The only qualification for study entry was that a
man needed a biopsy proven moderately well differentiated prostate cancer consistent with a Gleason score of 5
or 6 (range: 2-10).
The financial impact of transitioning men who choose to live with their cancer will be in the billions of
dollars saved, as minimally 50-60% of all prostate cancers fit this category. Additionally, men will be spared a
quality of life altering procedure including Radical Prostatectomy or Radiation. While patients in this study
protocol still qualify for these "definitive procedures" in the event they change their minds, there is no
indication that a more aggressive treatment is required. As the study results point out, 90% of the patients
suppressed their cancer while 10% remained stable at an average disease surveillance of 30 months. Minimally the
findings associated with this study give patients an additional option, with renewed hope for a better quality
of life, when prostate cancer is diagnosed.
Please feel free to contact me with questions or comments at 1-941-957-0007.
Ronald E. Wheeler, M.D.